We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Radioimmunotherapy of mice bearing breast tumors with <sup>177</sup>Lu-labeled trastuzumab.
- Authors
RASANEH, Samira; RAJABI, Hossein; AKHLAGHPOOR, Shahram; SHEYBANI, Shahab
- Abstract
Aim: In the present study, we investigated the therapeutic efficacy of trastuzumab labeled with lutetium-177 (177Lu) in mice bearing breast tumors. Materials and methods: Trastuzumab was labeled with 177Lu via D OTA as a chelator. In vitro and in vivo quality control tests of incorporated activity, immunoreactivity, stability of 177Lu-trastuzumab, biodistribution, and imaging studies were performed. Therapeutic efficacy and dosimetry studies were carried out in mice with breast tumors. Results: The good in vitro and in vivo quality control results suggested that 177Lu-trastuzumab could be used as a radioimmunotherapy agent. Reductions of 81% and 98% in the mean tumor volume for the group that received 177Lu-trastuzumab [7.4 MBq] were observed at 42 and 45 days after treatment, respectively. Conclusion: The results showed that 177Lu-trastuzumab could be considered as a possible new radiopharmaceutical agent for use in radioimmunotherapy of breast cancer in humans.
- Subjects
BREAST tumors; RADIOIMMUNOTHERAPY; LABORATORY mice; TRASTUZUMAB; IN vivo toxicity testing; QUALITY control; IN vitro studies
- Publication
Turkish Journal of Medical Sciences, 2012, Vol 42, Issue S1, p1292
- ISSN
1300-0144
- Publication type
Article
- DOI
10.3906/sag-1105-29